Experts discuss red flags that can trigger legal action against drug and device makers
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionBiologics/ biosimilars/ vaccinesBiotechnologyComplianceGenericsMedical DevicesPharmaceuticalsQuality Assurance and ControlUnited States